Streptococcus spp. and Enterococcus spp. in Humans and Animals: Virulence Potential, Antimicrobial Resistance, Genomic Trends and Approaches

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1359

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Molecular Biology and Physiology of Streptococci, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University – UERJ, Rio de Janeiro, Brazil
Interests: Enterococcus; Streptococcus

Special Issue Information

Dear Colleagues,

The Streptococcus genus comprises species implicated in human and animal diseases, in addition to other species used in dairy industries. Molecular genetics, taxonomic approaches, and phylogenomic investigations detected more than 100 Streptococcus species and 9 subspecies. These studies also contribute to the establishment of pathogenic groups (pyogenic, mitis, anginosus, salivarius, bovis, and mutans) related to zoonotic potential, multiple virulence mechanisms, and resistance to antimicrobial agents with impacts on health systems and economic losses to agriculture.

Enterococci are important causes of human infections, including bloodstream, surgical site, and urinary tract infections. Enterococci are also one of the most common zoonotic bacteria. Vancomycin-resistant enterococci are categorized as a serious public health threat, requiring prompt and sustained action. Moreover, enterococci resistant to penicillin, ampicillin, and vancomycin require other treatments such as daptomycin and linezolid. Therefore, characterizing antibiotic resistance mechanisms and monitoring emerging sequence types associated with resistance are required.

Multidrug-resistant (MDR) streptococci and enterococci species have been reported with increased frequency as pathogens of invasive infections and/or nosocomial outbreaks. A detailed understanding of multifactorial pathogenic mechanisms is essential for developing new therapeutic approaches and surveillance and control strategies relative to streptococcal diseases, including adhesive activities, metabolite exchange, cellular communication, and protection for antimicrobials and against host immune attacks. Consequently, the formation of bacterial biofilms leads to an increase in healthcare costs and extended hospitalization. The infectivity of the pathogens is linked to cell-surface components and/or secreted virulence factors. Additional studies remain necessary to investigate phenotypic and genotypic properties of virulence mechanisms and resistance to antimicrobial agents involved in multifactorial and complex adaptation strategies relative to host environmental conditions, such as the production of reactive oxidative species and neutrophil extracellular traps, survival within professional phagocytes, escaping the host’s immune response, and the modulation of host-cell signaling and cellular death. Invasive medical devices and/or empirical antibiotic therapy may contribute to the dissemination of invasive infections in hospitalized patients.

In this research topic, we welcome original research articles, mini reviews, reviews, and perspectives covering streptococcal pathogenesis in human, animal, and zoonotic infectious diseases:

  • Antimicrobial resistance features and multidrug-resistance mechanisms of Streptococcus spp. and Enterococcus spp.;
  • Virulence determinants that contribute to Streptococcus spp. and Enterococcus spp. diseases in human and animals;
  • Host–pathogen interactions involving Streptococcus spp. and Enterococcus spp.;
  • Host cell-signaling pathways during infection by Streptococcus spp. and Enterococcus spp. ;
  • Streptococcal glycans in pathogenesis.;
  • Innate immune modulation by pathogenic streptococci and enterococci.;
  • Fish disease caused by pathogenic Streptococcus spp.;
  • Streptococcus spp. isolated from clinical mastitis in dairy cattle.;
  • Enterococcus spp. isolated from food-producing animals and meat.;
  • Zoonotic potential of Streptococcus spp. and Enterococcus spp.

Dr. Prescilla Emy Nagao
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Streptococcus
  • Enterococcus
  • epidemiology
  • virulence
  • antimicrobial resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1247 KiB  
Article
Antibiotic Resistance and Presence of Persister Cells in the Biofilm-like Environments in Streptococcus agalactiae
by Pamella Silva Lannes-Costa, Isabelle Rodrigues Fernandes, João Matheus Sobral Pena, Brunno Renato Farias Verçoza Costa, Marcel Menezes Lyra da Cunha, Bernadete Teixeira Ferreira-Carvalho and Prescilla Emy Nagao
Antibiotics 2024, 13(11), 1014; https://doi.org/10.3390/antibiotics13111014 - 28 Oct 2024
Viewed by 753
Abstract
Objectives: This study investigated antibiotic resistance and presence of persister cells in Streptococcus agalactiae strains belonging to capsular types Ia/ST-103, III/ST-17, and V/ST-26 in biofilm-like environments. Results: S. agalactiae strains were susceptible to penicillin, clindamycin, and erythromycin. Resistance genes were associated with tet [...] Read more.
Objectives: This study investigated antibiotic resistance and presence of persister cells in Streptococcus agalactiae strains belonging to capsular types Ia/ST-103, III/ST-17, and V/ST-26 in biofilm-like environments. Results: S. agalactiae strains were susceptible to penicillin, clindamycin, and erythromycin. Resistance genes were associated with tetM (80%), tetO (20%), ermB (80%), and linB (40%). Persister cells were detected in bacterial strains exposed to high concentrations of penicillin, clindamycin, and erythromycin. S. agalactiae capsular type III/ST-17 exhibited the highest percentage of persister cells in response to penicillin and clindamycin, while type Ia/ST-103 presented the lowest percentages of persister cells for all antimicrobials tested. Additionally, persister cells were also detected at lower levels for erythromycin, regardless of capsular type or sequence type. Further, all S. agalactiae isolates presented efflux pump activity in ethidium bromide-refractory cell assays. LIVE/DEAD fluorescence microscopy confirmed the presence of >85% viable persister cells after antibiotic treatment. Conclusions: These findings suggest that persister cells play a key role in the persistence of S. agalactiae during antibiotic therapy, interfering with the treatment of invasive infections. Monitoring persister formation is crucial for developing strategies to combat recurrent infections caused by this pathogen. Full article
Show Figures

Figure 1

Back to TopTop